Acetazolamide, a carbonic anhydrase inhibitor first developed in the 1950s, is the diuretic making an unexpected comeback in heart failure treatment. Long overshadowed by more powerful loop diuretics like furosemide, acetazolamide re-entered the spotlight after the landmark ADVOR trial, published in the New England Journal of Medicine in August 2022, demonstrated that adding intravenous acetazolamide to standard loop diuretic therapy significantly improved fluid removal in patients hospitalized with acute decompensated heart failure. In that trial of 519 patients, successful decongestion at three days occurred in 42.2% of the acetazolamide group compared with 30.5% receiving placebo — a result that has since reshaped how cardiologists think about treating fluid overload in the hospital setting.
For readers following this site’s coverage of brain health and dementia care, this development matters more than it might first appear. Heart failure and cognitive decline share a well-documented relationship: chronic fluid overload, repeated hospitalizations, and poor cardiac output all contribute to reduced cerebral perfusion and accelerated cognitive deterioration. Any treatment that shortens hospital stays and improves fluid management has downstream implications for preserving brain function in older adults living with both conditions. This article covers how acetazolamide works, what the clinical evidence actually shows, where the limitations lie, and what caregivers and patients should understand about this old drug’s new role.
Table of Contents
- Why Is an Old Diuretic Making a Comeback in Heart Failure Treatment?
- How Acetazolamide Works Differently From Standard Diuretics
- What the ADVOR Trial Revealed About Different Types of Heart Failure
- Moving Beyond the Hospital — Oral Acetazolamide and Ongoing Trials
- Safety Concerns and the Renal Function Question
- Spironolactone and the Broader Diuretic Landscape
- What Comes Next for Acetazolamide in Heart Failure
- Conclusion
- Frequently Asked Questions
Why Is an Old Diuretic Making a Comeback in Heart Failure Treatment?
The short answer is that loop diuretics, while effective, run into a wall. Up to half of patients hospitalized with acute decompensated heart failure develop what clinicians call diuretic resistance — the kidneys adapt to furosemide and related drugs, and fluid removal slows or stalls. For decades, the standard response was to increase the dose or add a thiazide diuretic, but neither approach had strong randomized evidence behind it. Acetazolamide offered something different: it works on the proximal tubule of the kidney, an entirely separate segment from the loop of Henle where furosemide acts. this concept, known as sequential nephron blockade, means the two drugs together can shut down sodium and water reabsorption at multiple points along the kidney’s filtration system. What made the ADVOR trial so consequential was not just its positive result but its scale. It was the largest randomized trial of in-hospital diuretic therapy ever conducted at the time of publication.
The trial enrolled patients across multiple centers, randomizing them to receive either 500 mg of intravenous acetazolamide daily or placebo, both layered on top of standardized loop diuretic therapy. By the time of discharge, 78.8% of patients in the acetazolamide group had achieved successful decongestion compared with 62.5% in the placebo group. Hospital stays were roughly one day shorter — 8.8 days versus 9.9 days — a difference that no other diuretic had demonstrated in a randomized trial. For a healthcare system drowning in heart failure readmissions, even a single day carries real weight. The reason this drug had been sitting on the shelf is partly historical. When more potent loop diuretics became available, acetazolamide was relegated to niche uses like treating altitude sickness and glaucoma. Nobody had run a proper trial to test what many nephrologists and cardiologists had long suspected: that hitting the nephron at multiple points would work better than hammering a single segment harder. The ADVOR trial finally provided that evidence.
How Acetazolamide Works Differently From Standard Diuretics
Acetazolamide inhibits the enzyme carbonic anhydrase in the proximal tubule, which is the first major site of sodium and water reabsorption in the kidney. By blocking this enzyme, the drug prevents the kidney from reclaiming bicarbonate, and with it, sodium and water that would otherwise be pulled back into the bloodstream. Loop diuretics like furosemide, by contrast, act further downstream on the loop of Henle. The two mechanisms are complementary rather than redundant, which is why combining them produces more fluid removal than escalating the dose of either drug alone. One of the more clinically useful findings from the ADVOR trial involved a simple blood test. Patients whose baseline serum bicarbonate was 27 mmol/L or higher — roughly 45% of the trial population — showed the strongest response to acetazolamide.
This makes pharmacological sense: elevated bicarbonate indicates that the proximal tubule is actively reclaiming too much of it, giving acetazolamide a larger target to work against. For clinicians, this offers a practical way to identify which patients are most likely to benefit, turning a routine lab value into a treatment decision tool. However, this mechanism comes with a tradeoff that cannot be overlooked. Worsening renal function occurred in 41% of acetazolamide-treated patients in ADVOR compared with 19% in the placebo group. While most of these changes were transient and did not translate into worse long-term outcomes in the trial, the signal is real. Patients with already compromised kidney function — common in the elderly population most affected by both heart failure and dementia — need careful monitoring. This is not a drug to add casually, and the renal function numbers are precisely why guideline bodies have stopped short of a blanket endorsement.
What the ADVOR Trial Revealed About Different Types of Heart Failure
One of the most striking subgroup analyses from ADVOR was the finding that acetazolamide’s benefit held across all ejection fraction categories. Whether patients had heart failure with reduced ejection fraction, mid-range ejection fraction, or preserved ejection fraction, the drug improved decongestion to a similar degree. This is noteworthy because heart failure with preserved ejection fraction — the type most common in older adults and those with hypertension and diabetes — has historically been the hardest to treat. Most landmark heart failure drugs have shown their benefits primarily in patients with reduced ejection fraction, leaving a therapeutic gap for the preserved ejection fraction population. The trial also showed that baseline kidney function did not modify the drug’s effectiveness.
Patients with an estimated glomerular filtration rate at or below 40 mL per minute per 1.73 square meters responded similarly to those with better kidney function. And in a particularly relevant analysis published in JACC: Heart Failure in 2025, researchers found that patients with high diuretic resistance — measured by BAN-ADHF scores — who received acetazolamide achieved levels of diuresis comparable to non-resistant patients receiving loop diuretics alone. In other words, the drug appeared to overcome the very resistance problem that prompted its study in the first place. For the dementia care community, the preserved ejection fraction finding deserves special attention. Heart failure with preserved ejection fraction disproportionately affects older women, patients with multiple comorbidities, and individuals already at elevated risk for cognitive decline. A treatment that works across ejection fraction categories, rather than only in the subset with a weakened pump, has broader applicability to the patient population most likely to be managing both cardiac and cognitive challenges simultaneously.
Moving Beyond the Hospital — Oral Acetazolamide and Ongoing Trials
The ADVOR trial tested intravenous acetazolamide in hospitalized patients, which raises the practical question of whether an oral formulation could help patients manage fluid overload before it becomes severe enough to require admission. The ORION-A trial, a multicenter randomized study of 416 patients published in the Journal of Clinical Medicine in 2025, began addressing this question. It enrolled patients between April 2023 and October 2024 and tested oral acetazolamide at 250 mg three times daily for decompensated chronic heart failure — a lower dose, a different route, and a different clinical setting than ADVOR. Meanwhile, the ADA-HF trial, published in European Heart Journal Open in 2025, examined acetazolamide specifically as a chloride-sparing diuretic in heart failure, exploring yet another angle of its mechanism. A 2024 meta-analysis pooling data from four randomized controlled trials involving 634 patients confirmed that acetazolamide significantly increases both diuresis and natriuresis after 48 hours.
However — and this is the critical caveat — no mortality benefit has been demonstrated in any of these studies. The drug helps remove fluid faster and may shorten hospital stays, but whether it keeps patients alive longer or reduces rehospitalization rates remains unproven. This distinction between a surrogate outcome like decongestion and a hard outcome like survival matters enormously when weighing whether to adopt a new treatment broadly. For caregivers managing a loved one with both heart failure and cognitive impairment, the practical benefit of a shorter hospitalization is real and immediate — fewer days in the disorienting hospital environment, less delirium risk, faster return to familiar surroundings. But the absence of a mortality signal means acetazolamide is not yet in the same evidence category as drugs like sacubitril-valsartan or SGLT2 inhibitors, which have demonstrated survival benefits.
Safety Concerns and the Renal Function Question
The 41% rate of worsening renal function in the ADVOR trial’s acetazolamide arm, compared with 19% in placebo, is the number that gives clinicians pause. While the investigators noted that these changes were largely transient and not associated with worse clinical outcomes during the trial period, the heart failure population is not monolithic. Elderly patients with longstanding diabetes, chronic kidney disease, and polypharmacy represent a different risk profile than the average trial participant, and extrapolating safety data from a controlled trial to a frail 85-year-old on eight medications requires caution. The European Society of Cardiology updated its guidelines to acknowledge the new evidence for acetazolamide and combined diuretic strategies, noting that both acetazolamide and hydrochlorothiazide significantly reduced congestion at 72 hours when added to loop diuretics.
But the ESC Task Force explicitly concluded that more data on clinical outcomes — specifically mortality and rehospitalization — are still needed before establishing a formal class of recommendation. The European Heart Journal even published a “Great Debate” feature on whether acetazolamide should be considered first-line add-on therapy, a format reserved for questions where expert opinion genuinely diverges. For families navigating dementia care alongside heart failure management, the practical takeaway is that acetazolamide is a tool, not a cure. It should be discussed with the treating cardiologist, particularly for patients who are not responding adequately to loop diuretics alone. But it requires kidney function monitoring, and its use must be weighed against the cognitive and physical burden of additional lab draws and medication adjustments in patients for whom simplicity of care is itself a therapeutic goal.
Spironolactone and the Broader Diuretic Landscape
Acetazolamide is not the only older diuretic attracting renewed interest. A 2025 win ratio analysis of the TOPCAT trial found consistent benefits for spironolactone, a mineralocorticoid receptor antagonist, across cardiovascular death, cardiac arrest, and heart failure hospitalization in patients with preserved ejection fraction. This adds another option for the same population that stands to benefit from acetazolamide.
However, a separate 2025 study of 2,538 dialysis patients across 12 countries found that spironolactone failed to lower cardiovascular risk in that specific population — a reminder that a drug’s benefits do not always extend to every subset of patients with heart and kidney disease. The broader picture is that heart failure treatment is moving toward layered diuretic strategies rather than dose escalation of a single agent. For patients and caregivers, this means the medication list may become more complex, but each drug is doing a distinct job at a different point in the kidney. Understanding this logic — that the goal is to block fluid reabsorption at multiple sites rather than overpower it at one — can help families engage more meaningfully with treatment decisions.
What Comes Next for Acetazolamide in Heart Failure
A 2025 study tracking temporal trends in acetazolamide prescribing after the ADVOR publication confirmed what many expected: clinical adoption is growing. Cardiologists are increasingly reaching for this drug when loop diuretics alone fall short, and the ongoing trials examining oral formulations and different dosing strategies will likely expand its role further. If the ORION-A and ADA-HF results hold up under scrutiny, acetazolamide may eventually transition from a hospital-only add-on to a tool used earlier in the course of decompensation, potentially keeping some patients out of the hospital altogether.
For those caring for someone with both heart failure and cognitive decline, the trajectory of this research is cautiously encouraging. Shorter hospitalizations, better fluid management, and the possibility of outpatient use all align with the broader goal of keeping vulnerable older adults stable, at home, and in familiar environments where cognitive function is best preserved. The evidence is not yet complete — mortality data remain elusive, and the renal safety question needs longer follow-up — but acetazolamide’s return from obscurity represents exactly the kind of pragmatic, evidence-driven progress that this patient population needs.
Conclusion
Acetazolamide’s revival in heart failure treatment is a case study in how old drugs can find new purpose when subjected to rigorous modern trials. The ADVOR trial established that adding this 1950s-era carbonic anhydrase inhibitor to standard loop diuretic therapy improves decongestion rates, shortens hospital stays, and works across all types of heart failure — including the preserved ejection fraction variant most common in older adults. Subsequent trials and meta-analyses have reinforced these findings, and clinical adoption is rising. At the same time, the elevated rate of worsening renal function, the absence of a proven mortality benefit, and the ESC’s decision to hold off on a formal recommendation all signal that this story is still being written.
For caregivers and patients managing heart failure alongside dementia or cognitive decline, the practical message is to ask about acetazolamide if standard diuretics are not controlling fluid overload effectively. A simple serum bicarbonate level can help identify who is most likely to respond. But expect close monitoring of kidney function and understand that this drug supplements rather than replaces the foundation of heart failure therapy. The ongoing shift toward combination diuretic strategies represents real progress — not a silver bullet, but a sharper set of tools for a disease that demands them.
Frequently Asked Questions
What is acetazolamide and why is it being used for heart failure now?
Acetazolamide is a carbonic anhydrase inhibitor originally developed in the 1950s, primarily used for altitude sickness and glaucoma. The 2022 ADVOR trial, published in the New England Journal of Medicine, demonstrated that adding it to loop diuretics improved fluid removal in hospitalized heart failure patients, prompting its revival as an add-on therapy for acute decompensated heart failure.
Does acetazolamide work for all types of heart failure?
Yes, according to subgroup analyses from the ADVOR trial. The drug showed consistent benefit across heart failure with reduced, mid-range, and preserved ejection fraction, with no significant interaction based on ejection fraction category. This is particularly relevant for older adults, who more commonly have preserved ejection fraction.
What are the main risks of acetazolamide in heart failure patients?
The primary safety concern is worsening renal function, which occurred in 41% of acetazolamide-treated patients in the ADVOR trial versus 19% in the placebo group. While most changes were transient, patients with pre-existing kidney disease or those taking multiple nephrotoxic medications need careful monitoring.
Has acetazolamide been shown to reduce deaths from heart failure?
No. While acetazolamide improves decongestion and shortens hospital stays, no randomized trial has yet demonstrated a mortality benefit. A 2024 meta-analysis of four trials involving 634 patients confirmed improved diuresis but found no effect on survival. This is a key reason guideline bodies have not yet issued a formal class of recommendation.
Can acetazolamide be taken as a pill at home, or is it only given in the hospital?
The ADVOR trial used intravenous acetazolamide in hospitalized patients, but the ORION-A trial published in 2025 tested oral acetazolamide at 250 mg three times daily for outpatient decompensated chronic heart failure. Results from this and similar trials will help determine whether the drug can be used earlier and outside the hospital setting.
Which heart failure patients are most likely to benefit from acetazolamide?
Patients with elevated serum bicarbonate levels at or above 27 mmol/L showed the strongest response in the ADVOR trial. Roughly 45% of trial participants fell into this category. Additionally, patients with high diuretic resistance appeared to benefit the most, achieving fluid removal levels comparable to non-resistant patients on loop diuretics alone.
